| Literature DB >> 33799863 |
Daegwang Yoo1, Seo Young Park2, Dae Wook Hwang1, Jae Hoon Lee1, Ki Byung Song1, Woohyung Lee1, Yejong Park1, Eunsung Jun1, Song Cheol Kim1.
Abstract
BACKGROUND: Prediction of post-pancreaticoduodenectomy (PD) morbidity is difficult, especially in the early postoperative period when CT (Computed Tomography) scans are not available. Elevated serum amylase and lipase in postoperative day 0 or 1 may be used to define postoperative acute pancreatitis (POAP), but the existing literature does not agree on whether POAP is significantly associated with postoperative pancreatic fistula (POPF).Entities:
Keywords: amylases; pancreatic fistula; pancreaticoduodenectomy; pancreatitis; postoperative complications
Year: 2021 PMID: 33799863 PMCID: PMC8001526 DOI: 10.3390/jcm10061179
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Flow diagram showing the inclusion and exclusion criteria of original and secondary analysis.
Demographic characteristics and preoperative factors.
| POAP | Non-POAP | ||
|---|---|---|---|
| ( | ( | ||
| Age, years (mean ± SD) | 62.8 ± 9.4 | 63.9 ± 8.3 | 0.461 |
| Sex, | 0.268 | ||
| Female | 77 (40.3) | 17 (30.9) | |
| Male | 114 (59.7) | 38 (69.1) | |
| BMI, kg/m2 (mean ± SD) | 24.4 ± 3.1 | 24.0 ± 3.0 | 0.404 |
| ASA score, | 0.448 | ||
| Grade I | 21 (11.0) | 6 (10.9) | |
| Grade II | 156 (81.7) | 42 (76.4) | |
| Grade ≥ III | 14 (7.3) | 7 (12.7) | |
| Preoperative CEA (mean ± SD) | 168.4 ± 221.6 | 177.8 ± 296.2 | 0.798 |
| Preoperative CA 19-9 (mean ± SD) | 0.77 ± 0.18 | 0.78 ± 0.21 | 0.801 |
| Preoperative biliary/pancreatic drainage, | 0.409 | ||
| No | 83 (43.5) | 28 (50.9) | |
| Yes | 108 (56.5) | 27 (49.1) | |
| Preoperative cholangitis, | 0.733 | ||
| No | 150 (78.5) | 45 (81.8) | |
| Yes | 41 (21.5) | 10 (18.2) | |
| ERAS group, | 1.000 | ||
| Conventional group | 95 (49.7) | 28 (50.9) | |
| Intervention group | 96 (50.3) | 27 (49.1) | |
| Preoperative pancreatic duct size (mean ± SD) | 3.2 ± 2.1 | 4.1 ± 2.1 | 0.005 |
| Pancreatic texture | < 0.0001 | ||
| Soft | 138 (74.2) | 23 (41.8) | |
| Firm | 48 (25.8) | 32 (58.2) | |
| Pancreaticojejunostomy method, | 1.000 | ||
| Duct-to-mucosa | 172 (90.1) | 49 (89.1) | |
| Dunking | 19 (9.9) | 6 (10.9) | |
| Tumor type, | 0.869 | ||
| Adenocarcinoma | 138 (72.3) | 41 (74.5) | |
| Others | 53 (27.7) | 14 (25.5) | |
| Tumor location, | 0.004 | ||
| Ampulla of Vater | 32 (16.8) | 8 (14.5) | |
| Distal bile duct | 61 (31.9) | 6 (10.9) | |
| Duodenum | 12 (6.3) | 2 (3.6) | |
| Pancreas | 86 (45.0) | 39 (70.9) | |
| Cancer, | 1.000 | ||
| No | 48 (25.1) | 14 (25.5) | |
| Yes | 143 (74.9) | 41 (74.5) | |
| Retrieved lymph nodes in adenocarcinoma patients (mean ± SD) | 20.4 ± 8.6 | 19.1 ± 7.6 | 0.371 |
| Resection margin status, | 0.948 | ||
| R0 | 174 (91.0) | 51 (92.5) | |
| R1 | 17 (9.0) | 4 (7.5) |
Postoperative complications.
| POAP | Non-POAP | ||
|---|---|---|---|
| ( | ( | ||
| Total complications | 0.255 | ||
| No | 93 (48.7) | 22 (40.0) | |
| Yes | 98 (51.3) | 33 (60.0) | |
| Severe complications (Clavien–Dindo ≥ IIIa) | 0.333 | ||
| No | 174 (91.1) | 47 (85.5) | |
| Yes | 17 (8.9) | 8 (14.5) | |
| CR-POPF (Grade B or C) | 1.000 | ||
| No | 177 (92.7) | 51 (92.7) | |
| Yes | 14 (7.3) | 4 (7.3) | |
| Delayed gastric emptying | 0.685 | ||
| No | 182 (95.3) | 51 (92.7) | |
| Yes | 9 (4.7) | 4 (7.3) | |
| Post-pancreatectomy hemorrhage | 1.000 | ||
| No | 187 (97.9) | 54 (98.2) | |
| Yes | 4 (2.1) | 1 (1.8) |
Univariable and multivariable analyses of total postoperative complication rate after backward elimination by forcing the inclusion of postoperative acute pancreatitis (POAP).
| Univariable | Multivariable | ||||
|---|---|---|---|---|---|
| Variable | Odds Ratio | Odds Ratio | |||
| POAP | 0.703 (0.378–1.286) | 0.256 | 0.735 (0.393–1.356) | 0.327 | |
| Age | 1.015 (0.988–1.044) | 0.280 | |||
| Sex (Ref: Male) | 0.867 (0.518–1.453) | 0.589 | |||
| BMI | 0.954 (0.877–1.036) | 0.264 | |||
| ASA score (Ref: I) | 0.151 | 0.163 | |||
| II | 1.383 (0.617–3.159) | 0.432 | 1.421 (0.630–3.268) | 0.399 | |
| III | 3.125 (0.959–11.130) | 0.066 | 3.110 (0.946–11.158) | 0.069 | |
| Preoperative CEA | 1.001 (1.000–1.002) | 0.163 | |||
| Preoperative CA19-9 | 0.999 (0.262–3.820) | 0.998 | |||
| Preoperative biliary/pancreatic drainage | 0.883 (0.532–1.460) | 0.627 | 0.870 (0.520–1.452) | 0.595 | |
| Preoperative cholangitis | 0.891 (0.480–1.657) | 0.715 | |||
| ERAS group | 0.907 (0.549–1.497) | 0.701 | |||
| Preoperative pancreatic duct size | 0.982 (0.866–1.112) | 0.771 | |||
| Pancreatic texture | 0.806 (0.468–1.382) | 0.435 | |||
| Pancreaticojejunostomy method | 1.358 (0.591–3.246) | 0.477 | |||
| Tumor location (Ref: Pancreas) | 0.718 | ||||
| Ampulla of Vater | 0.686 (0.332–1.400) | 0.302 | |||
| Distal common bile duct | 1.034 (0.570–1.884) | 0.913 | |||
| Duodenum | 1.118 (0.367–3.572) | 0.845 | |||
| Cancer | 1.001 (0.560–17.783) | 0.996 | |||
| Resection margin status | 1.484 (0.601–3.881) | 0.400 | |||
Univariable and multivariable analyses of severe complications (Clavien–Dindo ≥ IIIa) after backward elimination by forcing the inclusion of POAP.
| Univariable | Multivariable | ||||
|---|---|---|---|---|---|
| Variable | Odds Ratio | Odds Ratio | |||
| POAP | 0.574 (0.239–1.481) | 0.227 | 0.647 (0.258–1.747) | 0.367 | |
| Age | 1.034 (0.987–1.089) | 0.178 | 1.046 (0.993–1.109) | 0.108 | |
| Sex (Ref: Male) | 0.477 (0.168–1.179) | 0.130 | 0.316 (0.099–0.903) | 0.038 | |
| BMI | 1.003 (0.872–1.146) | 0.971 | |||
| ASA score (Ref: I) | 0.044 | ||||
| II | NA * | 0.989 | |||
| III | NA * | 0.990 | |||
| Preoperative CEA | 1.000 (0.998–1.002) | 0.866 | |||
| Preoperative CA19-9 | 0.661 (0.066–5.778) | 0.717 | 0.157 (0.011–1.905) | 0.154 | |
| Preoperative biliary/pancreatic drainage | 0.735 (0.317–1.692) | 0.467 | 0.535 (0.212–1.314) | 0.175 | |
| Preoperative cholangitis | 0.705 (0.199–1.962) | 0.540 | |||
| ERAS group | 1.569 (0.683–3.752) | 0.294 | |||
| Preoperative pancreatic duct size | 1.018 (0.805–1.208) | 0.856 | |||
| Pancreaticojejunostomy method | 1.233 (0.277–3.940) | 0.749 | |||
| Pancreatic texture | 0.811 (0.343–2.013) | 0.637 | |||
| Tumor location (Ref: Pancreas) | 0.570 | ||||
| Ampulla of Vater | 0.386 (0.059–1.453) | 0.220 | |||
| Distal common bile duct | 0.856 (0.312–2.148) | 0.748 | |||
| Duodenum | 0.564 (0.030–3.160) | 0.594 | |||
| Cancer | 1.390 (0.534–4.330) | 0.529 | |||
| Resection margin status | 3.125 (0.945–8.976) | 0.043 | 3.451 (0.987–10.794) | 0.039 | |
* The results could not be calculated due to the existence of zero cells.
Univariable and multivariable analyses of clinically relevant postoperative pancreatic fistula (CR-POPF) after backward elimination by forcing the inclusion of POAP.
| Univariable | Multivariable | ||||
|---|---|---|---|---|---|
| Variable | Odds Ratio | Odds Ratio | |||
| POAP | 1.008 (0.344–3.677) | 0.989 | 0.998 (0.310–3.886) | 0.998 | |
| Age | 1.064 (1.003–1.137) | 0.051 | 1.075 (1.008–1.154) | 0.036 | |
| Sex (Ref: Male) | 0.301 (0.068–0.944) | 0.063 | 0.263 (0.056–0.888) | 0.050 | |
| BMI | 1.017 (0.866–1.186) | 0.838 | |||
| ASA score (Ref: I) | 0.110 | ||||
| II | NA * | 0.990 | |||
| III | NA * | 0.989 | |||
| Preoperative CEA | 1.002 (1.000–1.003) | 0.016 | |||
| Preoperative CA19-9 | 4.822 (0.414–48.984) | 0.192 | |||
| Preoperative biliary/pancreatic drainage | 3.095 (1.073–11.175) | 0.052 | |||
| Preoperative cholangitis | 0.750 (0.169–2.388) | 0.660 | 0.384 (0.078–1.363) | 0.177 | |
| ERAS group | 0.359 (0.112–0.985) | 0.059 | 0.347 (0.102–1.017) | 0.066 | |
| Preoperative pancreatic duct size | 0.832 (0.555–1.099) | 0.298 | |||
| Pancreaticojejunostomy method | 1.114 (0.169–4.260) | 0.890 | |||
| Pancreatic texture | 0.993 (0.370–2.949) | 0.990 | |||
| Tumor location (Ref: Pancreas) | 0.011 | ||||
| Ampulla of Vater | 1.263 (0.176–6.125) | 0.785 | |||
| Distal common bile duct | 4.714 (1.633–15.56) | 0.006 | |||
| Duodenum | NA * | 0.989 | |||
| Cancer | 1.746 (0.552–7.726) | 0.392 | |||
| Resection margin status | 3.462 (0.906–10.956) | 0.045 | 2.970 (0.700–11.004) | 0.113 | |
* The results could not be calculated due to the existence of zero cells.